Education/CredentialsMasters of Sciences: Harvard School of Public Health (Epidemiology)Clinical Research Fellowship: T.I.M.I. Study Group, Harvard UniversityCardiovascular Disease Fellowship: Jackson Memorial HospitalInternal Medicine Residency: Jackson Memorial HospitalMedical Degree: Robert Wood Johnson Medical SchoolUndergraduate Degree: Cook College, Rutgers University Board Certifications & LicensesAmerican Board of Internal Medicine (Cardiovascular Disease) (Certification Date: 2012-11-02) - (Recertification Date: 2022-12-29) SpecialtiesCardiovascular DiseaseEchocardiographyInternal MedicineNuclear Cardiology Contact Information Medical Sciences Building 3354A Office 513-558-6573 Email steendl@ucmail.uc.edu Clinical Interests CardiologyCardiovascular DiseaseObesityShortness of Breath Peer Reviewed Publications O'Donoghue ML, Braunwald E, White HD, Steen DL, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP. 2014. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA, 312 10, 1006-15Steen, D.L. 2014. The Revised ACC/AHA/HRS Guidelines for the Management of Patients With Atrial Fibrillation. http://anticoagulation.cardiosource.org. September 25, 2014. Accessed Oct 2, 2014. http://anticoagulation.cardiosource.org/Hot-Topics/2014/09/Revised-Guidelines-for-the-Management-of-Patients-With-Atrial-Fibrillation.aspx , , Steen, Dylan L; Bhatt, Deepak L 2014. Statin potency associated with incident diabetes in a real-world evaluation. Evidence-based medicine, 19 2, 68Steen D.L,, O’Donoghue M.L. 2013. Inhibitors for the Reduction of Cardiovascular Events. Cardiology and Therapy. Cardiology and Therapy, 2 2, 125Steen D.L. 2013. A Middle-Aged Man With AFib and Mechanical Heart Valve. http://anticoagulation.cardiosource.org, , Steen DL, Khera AV, Cannon CP 2013. Anacetrapib: Potential for the prevention and treatment of coronary heart disease. Research Reports in Clinical Cardiology, 4 , 39Steen, Dylan L; Cannon, Christopher P; Lele, Suhas S; Rajapurkar, Mohan M; Mukhopadhyay, Banibrata; Scirica, Benjamin M; Murphy, Sabina A; Morrow, David A 2013. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clinical cardiology, 36 3, 139-45Steen, Dylan L; O'Donoghue, Michelle L 2013. Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiology and therapy, 2 2, 125-34Hebert, Kathy; Quevedo, Henry C; Tamariz, Leonardo; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M 2012. Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 17 2, 113-22Steen DL, Wiviott SD, Cannon CP 2012. HDL and CETP Inhibition http://www.cardiosource.org/Science-And-Quality/Expert-Opinions-and-Cases/Hot-Topics/2012/02/HDL-and-CETP-Inhibition.aspx, , Steen, Dylan L; Cannon, Christopher P 2012. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Reviews in cardiovascular medicine, 13 1, e48-51Hebert K, Dias A, Franco E, Tamariz L, Steen D, Arcement LM 2011. Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program. Congestive Heart Failure, 17 6, 309Hebert, Kathy; Lopez, Barbara; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M . Prevalence of electrocardiographic abnormalities in a systolic heart failure disease management population by race, ethnicity, and sex. Congestive heart failure (Greenwich, Conn.), 16 1, 21-6
Peer Reviewed Publications O'Donoghue ML, Braunwald E, White HD, Steen DL, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP. 2014. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA, 312 10, 1006-15Steen, D.L. 2014. The Revised ACC/AHA/HRS Guidelines for the Management of Patients With Atrial Fibrillation. http://anticoagulation.cardiosource.org. September 25, 2014. Accessed Oct 2, 2014. http://anticoagulation.cardiosource.org/Hot-Topics/2014/09/Revised-Guidelines-for-the-Management-of-Patients-With-Atrial-Fibrillation.aspx , , Steen, Dylan L; Bhatt, Deepak L 2014. Statin potency associated with incident diabetes in a real-world evaluation. Evidence-based medicine, 19 2, 68Steen D.L,, O’Donoghue M.L. 2013. Inhibitors for the Reduction of Cardiovascular Events. Cardiology and Therapy. Cardiology and Therapy, 2 2, 125Steen D.L. 2013. A Middle-Aged Man With AFib and Mechanical Heart Valve. http://anticoagulation.cardiosource.org, , Steen DL, Khera AV, Cannon CP 2013. Anacetrapib: Potential for the prevention and treatment of coronary heart disease. Research Reports in Clinical Cardiology, 4 , 39Steen, Dylan L; Cannon, Christopher P; Lele, Suhas S; Rajapurkar, Mohan M; Mukhopadhyay, Banibrata; Scirica, Benjamin M; Murphy, Sabina A; Morrow, David A 2013. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clinical cardiology, 36 3, 139-45Steen, Dylan L; O'Donoghue, Michelle L 2013. Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiology and therapy, 2 2, 125-34Hebert, Kathy; Quevedo, Henry C; Tamariz, Leonardo; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M 2012. Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 17 2, 113-22Steen DL, Wiviott SD, Cannon CP 2012. HDL and CETP Inhibition http://www.cardiosource.org/Science-And-Quality/Expert-Opinions-and-Cases/Hot-Topics/2012/02/HDL-and-CETP-Inhibition.aspx, , Steen, Dylan L; Cannon, Christopher P 2012. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Reviews in cardiovascular medicine, 13 1, e48-51Hebert K, Dias A, Franco E, Tamariz L, Steen D, Arcement LM 2011. Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program. Congestive Heart Failure, 17 6, 309Hebert, Kathy; Lopez, Barbara; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M . Prevalence of electrocardiographic abnormalities in a systolic heart failure disease management population by race, ethnicity, and sex. Congestive heart failure (Greenwich, Conn.), 16 1, 21-6
O'Donoghue ML, Braunwald E, White HD, Steen DL, Lukas MA, Tarka E, Steg PG, Hochman JS, Bode C, Maggioni AP, Im K, Shannon JB, Davies RY, Murphy SA, Crugnale SE, Wiviott SD, Bonaca MP, Watson DF, Weaver WD, Serruys PW, Cannon CP. 2014. Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA, 312 10, 1006-15Steen, D.L. 2014. The Revised ACC/AHA/HRS Guidelines for the Management of Patients With Atrial Fibrillation. http://anticoagulation.cardiosource.org. September 25, 2014. Accessed Oct 2, 2014. http://anticoagulation.cardiosource.org/Hot-Topics/2014/09/Revised-Guidelines-for-the-Management-of-Patients-With-Atrial-Fibrillation.aspx , , Steen, Dylan L; Bhatt, Deepak L 2014. Statin potency associated with incident diabetes in a real-world evaluation. Evidence-based medicine, 19 2, 68Steen D.L,, O’Donoghue M.L. 2013. Inhibitors for the Reduction of Cardiovascular Events. Cardiology and Therapy. Cardiology and Therapy, 2 2, 125Steen D.L. 2013. A Middle-Aged Man With AFib and Mechanical Heart Valve. http://anticoagulation.cardiosource.org, , Steen DL, Khera AV, Cannon CP 2013. Anacetrapib: Potential for the prevention and treatment of coronary heart disease. Research Reports in Clinical Cardiology, 4 , 39Steen, Dylan L; Cannon, Christopher P; Lele, Suhas S; Rajapurkar, Mohan M; Mukhopadhyay, Banibrata; Scirica, Benjamin M; Murphy, Sabina A; Morrow, David A 2013. Prognostic evaluation of catalytic iron in patients with acute coronary syndromes. Clinical cardiology, 36 3, 139-45Steen, Dylan L; O'Donoghue, Michelle L 2013. Lp-PLA2 Inhibitors for the Reduction of Cardiovascular Events. Cardiology and therapy, 2 2, 125-34Hebert, Kathy; Quevedo, Henry C; Tamariz, Leonardo; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M 2012. Prevalence of conduction abnormalities in a systolic heart failure population by race, ethnicity, and gender. Annals of noninvasive electrocardiology : the official journal of the International Society for Holter and Noninvasive Electrocardiology, Inc, 17 2, 113-22Steen DL, Wiviott SD, Cannon CP 2012. HDL and CETP Inhibition http://www.cardiosource.org/Science-And-Quality/Expert-Opinions-and-Cases/Hot-Topics/2012/02/HDL-and-CETP-Inhibition.aspx, , Steen, Dylan L; Cannon, Christopher P 2012. Atherosclerosis. Effects of evacetrapib administered as monotherapy or in combination with statins. Reviews in cardiovascular medicine, 13 1, e48-51Hebert K, Dias A, Franco E, Tamariz L, Steen D, Arcement LM 2011. Open access to an outpatient intravenous diuresis program in a systolic heart failure disease management program. Congestive Heart Failure, 17 6, 309Hebert, Kathy; Lopez, Barbara; Dias, Andre; Steen, Dylan L; Colombo, Rosario A; Franco, Emiliana; Neistein, Sholom; Arcement, Lee M . Prevalence of electrocardiographic abnormalities in a systolic heart failure disease management population by race, ethnicity, and sex. Congestive heart failure (Greenwich, Conn.), 16 1, 21-6